Sterling Pharma Solutions Acquires Novartis Ringaskiddy API Manufacturing Facility

GHO Capital Acquires Majority Stake in Sterling Pharma Solutions

February 28, 2019

Pharmaceuticals

GHO Capital has acquired a majority stake in Sterling Pharma Solutions alongside management. The investment will support Sterling's international expansion and accelerate growth of its specialist API development and GMP manufacturing capabilities from its UK base in Newcastle upon Tyne.

Sterling Pharma Solutions Acquires Alcami's Germantown (WI) API Facility

October 1, 2020

Pharmaceuticals

Sterling Pharma Solutions, a portfolio company of GHO Capital Partners, has acquired Alcami’s Germantown, Wisconsin API development and manufacturing facility. The facility expands Sterling’s US footprint and adds cGMP capacity for complex and hazardous API projects, including plant-scale hydrogenation and cryogenic reactions.

Sterling Pharma Solutions Acquires CiVentiChem US Facility in Cary, North Carolina

April 3, 2019

Pharmaceuticals

UK-based CDMO Sterling Pharma Solutions, a portfolio company of GHO Capital, has acquired the CiVentiChem US facility in Cary, North Carolina to establish a local presence for its North American clients and expand its chemistry development and kilo-scale cGMP capabilities. The acquisition supports Sterling’s strategy to build a global chemistry services business and follows GHO Capital’s majority investment in Sterling earlier this year.

GHO Capital and Partners Group Invest in Sterling Pharma Solutions

May 25, 2023

Pharmaceuticals

GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.

Sterling Pharma Solutions Acquires ADC Biotechnology

April 7, 2021

Biotechnology

Sterling Pharma Solutions, a GHO Capital portfolio CDMO, has acquired ADC Biotechnology (ADC Bio), a Deeside-based bioconjugation and ADC development services business. The deal adds ADC capabilities and a Deeside facility to Sterling’s international network and includes multi-million pound investment to grow bioconjugation, analytical and cGMP ADC manufacturing capabilities.

ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M

March 9, 2021

Pharmaceuticals

ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.